Abstract: This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines, as well as, novel intermediates in the synthesis thereof.
Abstract: This invention discloses methods of using certain aryl-benzo[b]thiophene and benzo[b]furan compounds to block or inhibit cannabinoid receptors in mammals. It also discloses novel compounds which are antagonists of the cannabinoid receptors and also discloses pharmaceutical formulations which contain the compounds as an active ingredient.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
January 21, 1997
Assignee:
Eli Lilly and Company
Inventors:
George J. Cullinan, Kennan J. Fahey, Gary A. Koppel
Abstract: A pharmaceutical compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,Y is --CH.dbd.CH--, andZ is(i) phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(ii) --CHR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(iii) .dbd.CR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted, or(iv) ##STR2## where r is 0 or 1 to 3 and the phenyl rings are optionally substituted; provided that when Z is phenyl and m is 1, p is 1; and salts and esters thereof.
Type:
Grant
Filed:
November 22, 1994
Date of Patent:
December 31, 1996
Assignees:
Eli Lilly and Company, Universite Louis Pasteur, Lilly, S.A.
Inventors:
Jesus E. Carrera, Almudena R. Esteban, Andr e Mann, Ang ele Schoenfelder, Darryle D. Schoepp, Concepcion P. Tercero, Camille-Georges Wermuth
Abstract: Compounds having the formula ##STR1## methods for using such compounds to inhibit protein kinase C in animals, including man are useful as inhibitors of protein kinase C. Also disclosed are pharmaceutical compositions including such compounds and compounds having the formula.
Type:
Grant
Filed:
February 23, 1995
Date of Patent:
December 10, 1996
Assignee:
Eli Lilly and Company
Inventors:
Hong Hu, G. Erik Jagdmann, Jr., Jose S. Mendoza
Abstract: The present invention provides novel compounds that affect excitatory amino acid receptors and are useful in the treatment of neurological disorders. This invention also provides synthetic methods for the preparation of the novel compounds.
Type:
Grant
Filed:
October 13, 1994
Date of Patent:
November 19, 1996
Assignee:
Eli Lilly and Company
Inventors:
Lawrence J. Heinz, William H. W. Lunn, Darryle D. Schoepp
Abstract: This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines.
Abstract: This invention provides novel bicyclic compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides intermediates useful in the synthesis of excitatory amino acid antagonists.
Abstract: The present invention provides an odorless pharmaceutical composition of nizatidine. It also provides a novel form of nizatidine and a process for the preparation of this form.
Type:
Grant
Filed:
August 30, 1994
Date of Patent:
November 28, 1995
Assignee:
Eli Lilly and Company
Inventors:
Mary K. McCauley, Kenneth P. Moder, Jeffrey L. Speakman
Abstract: This invention provides a process for the stereocontrolled synthesis of cis-bicyclic compounds, including cis-hexahydro-6-isoquinolones, cis-dihydroisochromanones, cis-dihydrothiochromanones, and cisbicyclo[4.4.0]dec-3-ene-2-ones.
Type:
Grant
Filed:
March 31, 1993
Date of Patent:
October 24, 1995
Assignee:
Eli Lilly and Company
Inventors:
Vien V. Khau, Michael J. Martinelli, Barry C. Peterson, Kevin A. Sullivan
Abstract: The present invention provides novel decahydroisoquinoline derivatives which are useful as excitatory amino acid antagonists. The invention also provides for methods of using these derivatives to treat various neurological disorders.
Abstract: The present invention provides novel urea, thiourea and guanidine derivatives, pharmaceutical formulations thereof and a method of using same to prevent diabetic complications.
Type:
Grant
Filed:
November 14, 1994
Date of Patent:
August 15, 1995
Assignee:
Eli Lilly and Company
Inventors:
William F. Heath, Jr., Jill A. Panetta, John K. Shadle